Jim Simons Cytom X Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$70.6 Billion
Q3 2025

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 2,545,260 shares of CTMX stock, worth $9.82 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,545,260

Previous 1,862,200 36.68%

Holding current value

$9.82 Million

Previous $4.23 Million 92.07%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$1.76 - $3.23 $1.2 Million - $2.21 Million	683,060 Added 36.68%	2,545,260 $8.12 Million
Q2 2025 Aug 13, 2025	BUY	$0.43 - $2.99 $303,666 - $2.11 Million	706,200 Added 61.09%	1,862,200 $4.23 Million
Q1 2025 May 14, 2025	SELL	$0.58 - $1.14 $110,663 - $217,511	-190,800 Reduced 14.17%	1,156,000 $739,000
Q4 2024 Feb 13, 2025	BUY	$0.86 - $1.29 $285,348 - $428,022	331,800 Added 32.69%	1,346,800 $1.39 Million
Q3 2024 Nov 13, 2024	SELL	$1.12 - $1.51 $188,184 - $253,713	-168,022 Reduced 14.2%	1,015,000 $1.2 Million

Q2 2024 Aug 09, 2024	SELL	$1.21 - $5.13 $60,231 - $255,361	-49,778 Reduced 4.04%	1,183,022 $1.44 Million
Q1 2024 May 13, 2024	SELL	$1.41 - $2.74 $130,988 - $254,546	-92,900 Reduced 7.01%	1,232,800 $2.69 Million
Q4 2023 Feb 13, 2024	BUY	$1.07 - $1.55 $423,292 - $613,180	395,600 Added 42.53%	1,325,700 $2.06 Million
Q3 2023 Nov 14, 2023	SELL	$1.26 - $1.87 $242,298 - $359,601	-192,300 Reduced 17.13%	930,100 $1.2 Million
Q2 2023 Aug 11, 2023	BUY	$1.41 - $1.92 $383,661 - $522,432	272,100 Added 32.0%	1,122,400 $1.93 Million
Q1 2023 May 12, 2023	SELL	$1.48 - $2.88 $725,901 - $1.41 Million	-490,474 Reduced 36.58%	850,300 $1.28 Million
Q4 2022 Feb 13, 2023	SELL	$1.19 - $1.91 $553,142 - $887,817	-464,826 Reduced 25.74%	1,340,774 $2.15 Million
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $432,146 - $692,137	351,339 Added 24.16%	1,805,600 $2.62 Million
Q2 2022 Aug 12, 2022	BUY	$1.53 - $2.89 $854,292 - $1.61 Million	558,361 Added 62.32%	1,454,261 $2.66 Million
Q1 2022 May 13, 2022	BUY	$2.67 - $4.68 $1.04 Million - $1.83 Million	390,400 Added 77.23%	895,900 $2.39 Million
Q4 2021 Feb 11, 2022	SELL	$3.87 - $7.39 $1.51 Million - $2.88 Million	-389,100 Reduced 43.49%	505,500 $2.19 Million
Q3 2021 Nov 12, 2021	SELL	$4.32 - $6.43 $568,512 - $846,188	-131,600 Reduced 12.82%	894,600 $4.55 Million
Q2 2021 Aug 13, 2021	SELL	$6.33 - $9.91 $2.7 Million - $4.23 Million	-426,368 Reduced 29.35%	1,026,200 $6.5 Million
Q1 2021 May 13, 2021	SELL	$6.6 - $9.0 $4.04 Million - $5.51 Million	-611,932 Reduced 29.64%	1,452,568 $11.2 Million
Q4 2020 Feb 10, 2021	SELL	$6.47 - $7.9 $1.55 Million - $1.9 Million	-240,100 Reduced 10.42%	2,064,500 $13.5 Million
Q3 2020 Nov 13, 2020	SELL	$6.55 - $8.83 $301,765 - $406,806	-46,071 Reduced 1.96%	2,304,600 $15.3 Million
Q2 2020 Aug 13, 2020	BUY	$7.4 - $14.64 $1.06 Million - $2.09 Million	142,671 Added 6.46%	2,350,671 $19.6 Million
Q1 2020 May 14, 2020	BUY	$3.61 - $8.6 $522,471 - $1.24 Million	144,729 Added 7.01%	2,208,000 $16.9 Million
Q4 2019 Feb 13, 2020	BUY	$5.17 - $8.91 $2.75 Million - $4.73 Million	530,971 Added 34.65%	2,063,271 $17.1 Million
Q3 2019 Nov 13, 2019	BUY	$7.38 - $12.25 $924,714 - $1.53 Million	125,300 Added 8.91%	1,532,300 $11.3 Million
Q2 2019 Aug 12, 2019	BUY	$9.35 - $11.41 $1.09 Million - $1.33 Million	116,400 Added 9.02%	1,407,000 $15.8 Million
Q1 2019 May 14, 2019	SELL	$9.5 - $19.16 $258,400 - $521,152	-27,200 Reduced 2.06%	1,290,600 $13.9 Million
Q4 2018 Feb 13, 2019	BUY	$12.69 - $18.61 $16.7 Million - $24.5 Million	1,317,800 New	1,317,800 $19.9 Million

Others Institutions Holding CTMX

# of Institutions

109

Shares Held

121M

Call Options Held

1.49M

Put Options Held

258K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $255M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account